NCT01557569View on ClinicalTrials.gov

Clinical Efficacy of Atomoxetine for Methamphetamine Dependence

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

July 31, 2015

Conditions
Methamphetamine Dependence
Interventions
DRUG

Atomoxetine

During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)

DRUG

placebo

participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.

Trial Locations (1)

72034

UAMS, Psychiatric Research Institute, Center for Addiction Research, Little Rock

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of Arkansas

OTHER

NCT01557569 - Clinical Efficacy of Atomoxetine for Methamphetamine Dependence | Biotech Hunter | Biotech Hunter